ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00870870
Recruitment Status : Completed
First Posted : March 27, 2009
Results First Posted : June 1, 2018
Last Update Posted : June 1, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Gemcitabine Drug: Cisplatin Biological: IMC-A12 (cixutumumab) Biological: Cetuximab Drug: Carboplatin Phase 2

Detailed Description:
Participants with Stage IIIb or IV non-small cell lung cancer (NSCLC) who have not received previous chemotherapy will be stratified, based on disease histology (squamous versus [vs.] nonsquamous).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Study Start Date : March 2009
Actual Primary Completion Date : April 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)

Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met

*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)

Drug: Gemcitabine

1000 milligrams per square meter (mg/m^2) on Days 1 and 8 of each cycle

[First 6 cycles (18 weeks)]


Drug: Cisplatin

75 mg/m^2 on Day 1 of each cycle

[First 6 cycles (18 weeks)]


Biological: IMC-A12 (cixutumumab)

6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)

[First 6 cycles (18 weeks)]

Other Names:
  • Cixutumumab
  • LY3012217

Biological: Cetuximab

400 mg/m^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m^2 once per week thereafter

[First 6 cycles (18 weeks)]

Other Name: Erbitux®

Biological: IMC-A12 (cixutumumab)

10 mg/kg IV infusion, administered once every 2 weeks

(Maintenance therapy)

Other Names:
  • Cixutumumab
  • LY3012217

Biological: Cetuximab

500 mg/m^2 IV infusion, administered once every 2 weeks

(Maintenance therapy)

Other Name: Erbitux®

Drug: Carboplatin

Area under the curve (AUC) = 5, Day 1 of each cycle

[First 6 cycles (18 weeks)]

*Carboplatin will be replaced by Cisplatin


Active Comparator: GCiC (Gemcitabine/Cisplatin/Cetuximab)

Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met

*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)

Drug: Gemcitabine

1000 milligrams per square meter (mg/m^2) on Days 1 and 8 of each cycle

[First 6 cycles (18 weeks)]


Drug: Cisplatin

75 mg/m^2 on Day 1 of each cycle

[First 6 cycles (18 weeks)]


Biological: Cetuximab

400 mg/m^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m^2 once per week thereafter

[First 6 cycles (18 weeks)]

Other Name: Erbitux®

Biological: Cetuximab

500 mg/m^2 IV infusion, administered once every 2 weeks

(Maintenance therapy)

Other Name: Erbitux®

Drug: Carboplatin

Area under the curve (AUC) = 5, Day 1 of each cycle

[First 6 cycles (18 weeks)]

*Carboplatin will be replaced by Cisplatin





Primary Outcome Measures :
  1. Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] [ Time Frame: Randomization to measured progressive disease (PD) (up to 16.9 months) ]
    ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and the normalization of the tumour marker level. PR was defined as having at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Percentage of participants is calculated as a total number of participants with CR or PR / total number of participants treated * 100.


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Randomization to death due to any cause or censor (up to 30.4 months) ]
    OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.

  2. Progression-Free Survival (PFS) [ Time Frame: Randomization to PD or death due to any cause or censor (up to 16.9 months) ]
    PFS was defined as the duration from the date of randomization until disease progression or death due to any cause, whichever occurred first. Response was defined using RECIST, v 1.0 criteria. PD was defined as having a ≥20% increase in sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants who were alive and without disease progression, PFS was censored at the date of last objective tumor assessment. For participants who did not experience disease progression and were lost to follow-up, PFS was censored at the date of the last objective tumor assessment or the date of last contact.

  3. Time To Progression (TTP) [ Time Frame: Randomization to months until PD or censor (up to 16.9 months) ]
    TTP was defined as the duration from the date of randomization until the date of disease progression. Response was defined using RECIST v 1.0 criteria. PD was defined as having a ≥20% increase in the sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants without disease progression, TTP was censored at the date of last objective tumor assessment. For participants without disease progression and were subsequently lost to follow-up, TTP was censored at the date of last follow-up visit or at the date of last contact.

  4. Duration of Response [ Time Frame: Date of first response to the date of PD or death due to any cause or censor ( up to 15.5 months) ]
    The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of disease progression or death. Response was defined using RECIST v 1.0 criteria. CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as having at least a 30% decrease in sum of LD of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of disease progression.

  5. Number of Participants With Adverse Events (AEs) or Deaths [ Time Frame: Randomization to last dose of study medication (up to 11.7 months) plus 30-day safety follow-up ]
    Data presented are the number of participants who experienced 1 or more AEs, serious AEs (SAEs), and AEs that lead to death during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.

  6. Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity) [ Time Frame: Prior to first infusions of Cycles 1, 3, and 5 and 30 days following the end of therapy ]
  7. Maximum Concentration (Cmax) of Cixutumumab at Study Day 1 [ Time Frame: Day 1 ]
  8. Cmax of Cixutumumab for Cycle 1 [ Time Frame: Week 1 (Cycle 1, Day 1) ]
  9. Cmax of Cixutumumab for Cycle 3 [ Time Frame: Week 7 (Cycle 3, Day 1) ]
  10. Cmax of Cixutumumab Cycle 5 [ Time Frame: Week 13 (Cycle 5, Day 1) ]
  11. Minimum Concentration (Cmin) of Cixutumumab at Study Day 1 [ Time Frame: Day 1 ]
  12. Cmin of Cixutumumab for Cycle 1 [ Time Frame: Week 1 (Cycle 1, Day 1) ]
  13. Cmin of Cixutumumab for Cycle 3 [ Time Frame: Week 7 (Cycle 3, Day 1) ]
  14. Cmin of Cixutumumab for Cycle 5 [ Time Frame: Week 13 (Cycle 5, Day 1) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC
  • Has metastatic disease
  • Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST)
  • Has adequate hematologic function
  • Has adequate hepatic function
  • Has adequate renal function
  • Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Has uncontrolled brain metastases
  • Has leptomeningeal disease
  • Has received previous chemotherapy for NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)
  • Receiving any other investigational agent(s)
  • Has a history of treatment with other agents targeting the insulin-like growth factor (IGF) or the epidermal growth factor (EGF) receptor
  • Has a known allergy / history of hypersensitivity reaction to any of the treatment components
  • Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range [fasting glucose <160 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) and hemoglobin A1C≤ 7%] and that they are on a stable dietary or therapeutic regimen for this condition
  • Has an uncontrolled intercurrent illness
  • Pregnant or lactating
  • Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years
  • Has superior vena cava syndrome contraindicating hydration
  • Has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure
  • Has any National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy
  • Has significant third space fluid retention, requiring repeated drainage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00870870


Locations
United States, Alabama
ImClone Investigational Site
Anniston, Alabama, United States, 36207
United States, California
ImClone Investigational Site
La Jolla, California, United States, 92093
ImClone Investigational Site
Orange, California, United States, 92868
United States, Florida
ImClone Investigational Site
Orlando, Florida, United States, 32806
United States, Georgia
ImClone Investigational Site
Atlanta, Georgia, United States, 30341
United States, Illinois
ImClone Investigational Site
Chicago, Illinois, United States, 60612
ImClone Investigational Site
Chicago, Illinois, United States, 60637
United States, New Mexico
ImClone Investigational Site
Albuquerque, New Mexico, United States, 87131
United States, New York
ImClone Investigational Site
New York, New York, United States, 10011
ImClone Investigational Site
New York, New York, United States, 10021
ImClone Investigational Site
New York, New York, United States, 10032
United States, Ohio
ImClone Investigational Site
Cincinnati, Ohio, United States, 45247
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: E-mail: ClinicalTrials@ ImClone.com ImClone LLC

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00870870     History of Changes
Other Study ID Numbers: 13930
CP02-0860 ( Other Identifier: CDER )
CP13-0811 ( Other Identifier: ImClone, LLC )
I5A-IE-JAEF ( Other Identifier: Eli Lilly and Company )
First Posted: March 27, 2009    Key Record Dates
Results First Posted: June 1, 2018
Last Update Posted: June 1, 2018
Last Verified: May 2018

Keywords provided by Eli Lilly and Company:
Tumors
Antibodies, Monoclonal
Stage IIIb Metastatic Non-Small Cell Lung Cancer
Stage IV Metastatic Non-Small Cell Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Cisplatin
Carboplatin
Cetuximab
Antibodies, Monoclonal
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs